Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Jnana Therapeutics

    - PMLiVE

    Otsuka shares promising phase 3 results for sibeprenlimab in rare kidney disease IgAN

    The trial will continue to evaluate change in kidney function over two years

    - PMLiVE

    Otsuka Pharmaceutical to acquire Jnana Therapeutics in deal worth over $1.1bn

    The agreement includes a clinical-stage drug for the rare inherited metabolic disorder phenylketonuria

    - PMLiVE

    Roche enters into second collaboration with Jnana to address complex drug targets

    The Boston-based biotech will receive an upfront payment of $50m

    - PMLiVE

    EMA accepts Otsuka and Astex’s marketing authorisation application for acute myeloid leukaemia treatment 

    The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

    Biomarin

    FDA pauses BioMarin gene therapy trial

    The study for BMN 307 in genetic disease phenylketonuria will be paused while malignancies in mice are explored

    - PMLiVE

    FDA panel turns down Otsuka’s drug for rare kidney disease

    Unable to recommend expanded use of tolvaptan

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links